anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To find an ingredient having activities for extending a hair growth period and the obtain an agent for extending the hair growth period by using the ingredient as the active ingredient. SOLUTION: This agent for extending a hair growth period is obtained by using one or not less than two components selected from the group of extracts of Symphytum Officinale L., Curcuma domestica Valton, Zizyphus jujube Miller Var. inermis Rehder, Asarum sieboldii Miq., Coix lachryma-jobi L. var. ma-yuen Stapf, Stevia rebandiana Bertoni, Uncaria gambir Roxburgh, Gentiana lutea L., Humulus luplus L., Azukia angularis Ohwl, Isodon japonicus Hara, Arnica montana L., Mentha arvensis L., Glycyrrhiza glabra L., Poria cocos Wolf, Glycine max Merril, Perilla frutescens Britton var. acuta Kudo, Cinchona succirubra Pavon et Klitzch, Equisetum arvenes L., Prunus armeniaca L., Glycyrrhiza glabra L., Crataegus cuneata Siebold et Zuccarini, Cnidium Rhizome Makino, Cinnamoum cassia Blume, Ganoderma lucidum, Syzygum aromaticum Merrill et Perry and Citrus aurantium L. subsp. amara Engl.  and royal jelly as an active ingredient.
The invention discloses a preparation for restoring consciousness and calming nasal mucosa and a preparation method thereof. The preparation is a nasal drug composition preparation for treating cerebrovascular diseases. The nasal drug composition preparation is prepared from 30 to 50 parts by weight of borneol (or L-borneol), 3 to 9 parts by volume of synthetic musk essential oil, 2 to 6 parts by volume of turmeric root tuber essential oil and 30 to 40 parts by weight of cape jasmine fruit extract. The nasal drug composition preparation produces treatment effects through being absorbed by nasal mucosa and the nasal mucosa absorption process is mainly a passive absorption process. Drugs and fat-soluble drugs having relative molecular weight less than 1000 can be absorbed easily. The nasal drug composition preparation has high bioavailability near to 100%.
Inguinal hernia is a prevalent surgical condition in pediatric patients. Despite the efficacy of current treatment modalities, a certain recurrence rate still persists. Hence, our objective in this study is to introduce an innovative surgical technique designed to minimize surgical complications. We conducted a retrospective analysis on 809 pediatric cases that underwent laparoscopic repair with our innovative technique for inguinal hernia from June 2020 to June 2022. Demographic information, perioperative details, and postoperative follow-up outcomes were thoroughly assessed. All surgeries were conducted laparoscopically under general anesthesia. The procedure commenced by encircling the hernia sac with two sutures under laparoscopic guidance. Subsequently, the sac was exteriorized from the body using the two sutures, followed by ligation and excision of the hernia sac. The research findings demonstrate that the duration of unilateral and bilateral procedures was recorded as 15.9 ± 4.8 and 21.7 ± 3.9 min, respectively. Incision infection occurred in 7 patients (0.87%), and Male Complicated Inguinal Hernia (MCIH) was observed in 2 patients (0.23%). Notably, there were no occurrences of iatrogenic cryptorchidism, testicular atrophy, or recurrence (0%) during the follow-up period. In conclusion, our novel modification shows a notable reduction in postoperative recurrence rates and alleviates the impact of the procedure on the positioning of the testis or uterus. This modified technique is both safe and valuable, thus warranting broader adoption and promotion.
PURPOSE: To obtain the subject cosmetic having a dry touch and excellent in a fitting touch by compounding dimethylpolysiloxane having a specific viscosity, a powdery material, and a volatile oily component in a constant or larger amount in a specific ratio. CONSTITUTION: A powder-compounded cosmetic is prepared by adding a volatile oily component in an amount of >=60wt.% based on all the oily components of the cosmetic to a system comprising dimethylpolysiloxane having a viscosity of 3000-10000cps at 25 deg.C (in an amount of 0.1-10wt.% based on the whole amount of the cosmetic) and a powdery material (in an amount of 1-50wt.%). The volatile oily component is preferably a cyclic polysiloxane and is especially preferably compounded in an amount of 3-40wt.% based on the whole amount of the cosmetic. The powder-compounded cosmetic may be compounded with water in an amount of >=15wt.% based on the whole amount of the cosmetic to give an emulsion cosmetic. The emulsion cosmetic is especially preferably an oil-in- water type cosmetic. The cosmetic has a dry touch, does not cause 'YORE (uneven spreading)' which is the characteristic property of powder, and is excellent in a fitting touch.
PROBLEM TO BE SOLVED: To prepare the granules of a food, a medicine, etc., capable of emphasizing its flavor, fragrance, etc., excellent in texture, capable of being maintained in a good shape from their preparation time to their handling time. SOLUTION: This method for preparing the granules of a food, a medicine, etc., comprises mixing a powdery raw material with the powder of a binder having a melting point of 40-130 deg.C, heating and stirring the mixture at a higher temperature than the melting point of the binder powder or higher, simultaneously spraying the heated and melted products of solid fats containing a solid fat having a melting point of 40-120 deg.C in an amount of >=70% on the heated and stirred mixture, and subsequently cooling the mixture at a lower temperature than the melting point of the binder powder or lower. The powdery raw material includes various kinds of flavor materials and fragrant materials and is used in an amount of 70-95wt.%. The binder powder includes beef tallow and palm oil, and is used in an amount of 4-20wt.%. The solid fats are used in an amount of 1-20wt.%.  The solid fats are the extract fats of a flavor raw component and/or a fragrant raw component, or the heated mixture of a raw material solid fat with the flavor raw material and/or the fragrant raw material. The method for preparing the granules is effective for granulating the powder of a single spice such as pepper, the powder of a mixed spice such as curry powder, etc.
Parkinson's disease (PD) is typically a sporadic late-onset disorder, which has made it difficult to model in mice. Several transgenic mouse models bearing mutations in SNCA, which encodes alpha-Synuclein (α-Syn), have been made, but these lines do not express SNCA in a physiologically accurate spatiotemporal pattern, which limits the ability of the mice to recapitulate the features of human PD. Here, we generated knock-in mice bearing the G51D SNCA mutation. After establishing that their motor symptoms begin at 9 mo of age, we then sought earlier pathologies. We assessed the phosphorylation at Serine 129 of α-Syn in different tissues and detected phospho-α-Syn in the olfactory bulb and enteric nervous system at 3 mo of age. Olfactory deficit and impaired gut transit followed at 6 mo, preceding motor symptoms. The SncaG51D mice thus parallel the progression of human PD and will enable us to study PD pathogenesis and test future therapies.
Adults with dysphagia post stroke (within 4-16 weeks of onset) who have radiographically confirmed difficulties with thin liquid bolus control. Individuals will complete 24 sessions of tongue-pressure-profile training over 8-12 weeks.
The investigators will cross-randomize 120 drug shops enrolled in the parent Malkia Klabu effectiveness cluster-randomized controlled trial (CRCT; NCT05357144), stratified by CRCT study arm, to one of three initial conditions: 1. No feedback. AGYW customer feedback will be collected, but not shared with the shopkeeper. 2. Private feedback. Biweekly summarized reports of AGYW customer feedback will be given directly to shopkeepers. 3. Public feedback: Shopkeepers will get biweekly summarized reports of AGYW customer feedback, gold stars reflecting the level of AGYW customer feedback (e.g., 1-5 star rating) will be placed in the shop in a visible location, and shopkeepers will be invited to an awards ceremony every 6 months to recognize shopkeepers who receive high levels of positive AGYW customer feedback. The investigators will phase in the 2 interventions (Private and Public Feedback) on a staggered basis to control for both shop-specific and time-specific trends for the primary outcomes.
Eligible infants stable on high flow nasal cannula (nCPAP) therapy of 5-7 cm H20 achieved with a ventilator, an underwater "bubble" system, or a variable-flow device will be enrolled. A data acquisition cart will be placed at the subject's bedside to collect hemodynamic and respiratory parameters measured including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices. A neonatal chest belt, sized to the infant's chest circumference (nipple level) using warmed ultrasound gel applied to the belt beforehand, will collect regional lung volume measurements using electrical impedance tomography (EIT). Subject video recording will capture apnea events and the interventions used to resolve them such as positive pressure ventilation, repositioning, or stimulation. Data will be collected for 15 minutes on nCPAP.
This arm is composed by group-based interventions aiming to modify the self-management of the patients through the Prochaska and DiClemente transtheorical model. It is composed by weekly meetings, lasting up to 1 hour and a half, targeting eight patients per group. After the 12nd month of intervention, the meetings will be held each fifteen days untill the trial ending (18 months). The meetings will deal with lifestyle matters, such as nutrition, weight management, and physical activity, as well as medication adherence, blood glucose testing, and others. Whenever a care provider will be assigned to a group, he/she will go over untill the final of the trial, unless unexpected motivations appear. Patients achieving maintenance will receive green flag from the group-based interventions to avoid contamination. It is up to the care provider to perceive the readiness of the patient to another stage.
A use of carnosine for preparing a drug for colon cancer metastasis is to administer an effective amount of carnosine to an individual, wherein the carnosine dose of 42.5-850 mg/kg is administered to the individual to achieve an effective reduction in liver function index of alanine aminotransferase (ALT), aspartate aminotransferase (AST), aberrant crypt (AC) and aberrant crypt foci (ACF) as well as the expression of colon cancer-specific index of caudal type homeobox 2 (CDX2) and cytokeratin-20 (Krt20), thereby inhibiting colon cancer metastasis. In this way, the use of carnosine has a good ability to inhibit colon cancer metastasis and can further provide a reference for carnosine in inhibiting colon cancer metastasis. Thus, the present invention provides carnosine for reducing the production of aberrant crypt (AC) and aberrant crypt foci (ACF) in the colorectal tissue and the expression of caudal type homeobox 2 (CDX2) and cytokeratin-20 (Krt20), thereby inhibiting the colon cancer progression. In addition, the present invention can reduce the incidence of liver and lung tumors and the expression of caudal type homeobox 2 (CDX2) and cytokeratin-20 (Krt20) to inhibit colon cancer metastasis to the liver and lung. In the embodiments of the present invention, carnosine is administered at doses of 42.5 mg/kg, 85 mg/kg, 170 mg/kg or 850 mg/kg. Furthermore, it is found that the use of 85 mg/kg carnosine has the best carnosine effect for the preparation of the drug for colon cancer metastasis. In the present invention, ICR mice are used as experimental subjects, azoxymethane (AOM) is used to induce the colon cancer metastasis pattern of ICR mice, and carnosine is fed after colon cancer is formed so as to explore whether carnosine can inhibit colon cancer metastasis to the liver and lung, analyze the potential of carnosine in the production and metastasis of colon cancer, and evaluate the therapeutic potential of carnosine in human colon cancer.
FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to the improved method for preparing metoprolol that is the known medicinal agent used in treatment of patients with arrythmia and myocardium infarct. At the first stage p-(2-methoxyethyl)-phenol and epichlorohydrin are subjected for interaction in water as a solvent in the coarse of a base addition and excess of epichlorohydrin is evaporated at temperature 50-70 C and obtained 1-(2,3-epoxypropoxy)-4-(2-methoxyethyl)benzene is distilled then under reduced pressure. At the first stage prepared 1-(2,3-epoxypropoxy)-4-(2- methoxyethyl)benzene is subjected for interaction with isopropylamine to yield metoprolol-base that if necessary is converted to metoprolol tartrate or metoprolol succinate. Usually, the first stage is carried out in the presence of sodium hydroxide or potassium hydroxide. Prepared metoprolol-base can be purified by dissolving metoprolol-base in solvent taken among toluene, isobutylmethyl ketone and butyl acetate and extraction with solution of hydrochloric or sulfuric acid. Method is safe ecologically and allows preparing the end product with good yield and high purity degree. EFFECT: improved preparing method. 6 cl
Fibrodysplasia ossificans progressiva (FOP) is a rare congenital disorder characterized by abnormal bone formation due to ACVR1 gene mutations. The identification of the molecular mechanisms underlying the ectopic bone formation and expansion in FOP is critical for the effective treatment or prevention of HO. Here we find that Hh signaling activation is required for the aberrant ectopic bone formation in FOP. We show that the expression of Indian hedgehog (Ihh), a Hh ligand, as well as downstream Hh signaling, was increased in ectopic bone lesions in Acvr1R206H; ScxCre mice. Pharmacological treatment with an Ihh-neutralizing monoclonal antibody dramatically reduced chondrogenesis and ectopic bone formation. Moreover, we find that the activation of Yap in the FOP mouse model and the genetic deletion of Yap halted ectopic bone formation and decreased Ihh expression. Our mechanistic studies showed that Yap and Smad1 directly bind to the Ihh promoter and coordinate to induce chondrogenesis by promoting Ihh expression. Therefore, the Yap activation in FOP lesions promoted ectopic bone formation and expansion in both cell-autonomous and non-cell-autonomous manners. These results uncovered the crucial role of the Yap-Ihh axis in FOP pathogenesis, suggesting the inhibition of Ihh or Yap as a potential therapeutic strategy to prevent and reduce HO.
Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic ‎paradoxically causes an increase in pain, or an increase in sensitivity to pain. ‎This condition differs from tolerance, which is the need for increasing doses of ‎opioids to maintain a defined effect [see Dependence (9.3)]. Symptoms of OIH ‎include (but may not be limited to) increased levels of pain upon opioid dosage ‎increase, decreased levels of pain upon opioid dosage decrease, or pain from ‎ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only ‎if there is no evidence of underlying disease progression, opioid tolerance, ‎opioid withdrawal, or addictive behavior.‎

Cases of OIH have been reported, both with short-term and longer-term use of ‎opioid analgesics. Though the mechanism of OIH is not fully understood, ‎multiple biochemical pathways have been implicated. Medical literature suggests ‎a strong biologic plausibility between opioid analgesics and OIH and allodynia. If ‎a patient is suspected to be experiencing OIH, carefully consider appropriately ‎decreasing the dose of the current opioid analgesic or opioid rotation (safely ‎switching the patient to a different opioid moiety) [see Dosage and ‎Administration (2), Warnings and Precautions (5.7)].‎
The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity and diabetes. 

Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. 

The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. 

Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from refs. 2 and 3 with the author's permission). For further information, the reader is referred to a text on epidemiological methods.
PURPOSE: To obtain a medicine capable of suppressing metastasis of cancer by enhancing a specific saccharide transferase activity in a cancer cell or the tissue in the circumference of the cancer cell. CONSTITUTION: This cancer metastasis suppressor contains Nacetylglucosaminyltransferease III (GnT-III) or its gene as an active ingredient. The gene includes a rat GnT-III gene (having 1608 length of sequence and 1 sequence number) and human GnT-III gene (having 1593 length of sequence and 2 sequence number) or a gene hybridizing to the gene of the rat GnT-III or the human GnT-III and coding a protein exhibiting GnT-III activity. A method for applying the medicine includes e.g. a method for directly introducing GnT-III by a microinjection method while retaining the activity or a method for introducing GnT-III gene using virus, etc., and expressing GnT-III. The metastasis ability of the cancer cell is suppressed by introduction of GnT-III.
PROBLEM TO BE SOLVED: To prevent the occurrence of a medical mistake by correctly transmitting an instruction concerning a medical care to each department in a medical organization. SOLUTION: A host computer 1 to store a medical care plan of a patient is provided, and a plural number of sub computers 2 connected to it in a network are provided in each of the departments of a hospital. A patient tag issuing device 5 is provided at a reception desk, a medical care instruction slip issuing device 7 is provided in each of an examination room, a test room, a nurse station, a medication room, etc., and a label issuing machine 8 to issue labels recording discrimination information is provided in each of the medication room and an instrument room. The patient carries a patient tag with a patient code attached to it, and each of medical staffs carries an information code reader 9 to read and collate the code. The label with a used article code marked on it is attached on a used article. A medical instruction slip with the medical instruction based on the medical plan with the information code mentioned on it is issued at each of the departments. It is possible to easily confirm whether the used article such as a medical instrument, a medicine, etc., to be used for medical care practice is concerned with the corresponding patient or not by collation of the code.
The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. No intervention or any other procedure will be conducted during the study period of 36 weeks. Afterwards these subjects will be offered an EMDR therapy as provided in the intervention.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention relates to veterinary science. The method involves intramuscular introduction of metallosuccinate. The preparation is introduced to suckling pigs on 2nd, 12th and 25th postnatal days in dosages 1.5 ml, 2.0 ml and 3.0 ml respectively, and to milking sows in the same schedule in dosage 5.0 ml, and to pregnant sows - on 80th and 97th days in dosage 5.0 ml. ^ EFFECT: method improves productivity of the animals, reduces incidence of gastrointestinal disturbances, and provides higher safety of the livestock population. ^ 1 ex, 5 tbl
Maintenance hemodialysis hemodialysis and CKD patients in stage 4 or 5 (n=50) will be recruited for the study. A randomized, controlled, double-blind, cross-over study will be carried out. Following a 1-week baseline, participants will be assigned to receive snacks with pea hull fiber or control followed by a 4-week wash-out period, and then crossed over to the second intervention. Snacks with added pea hull fiber (15 g/d) and control will be provided to participants in identical packaging. Participants will collect 4 days of stools during the baseline week, week 5, 9, and 13 and analyzed for mineral content. Microbiota composition will be analyzed including microbial diversity, qPCR to quantify changes and 16S rRNA sequencing to identify pea hull fiber effects on specific bacteria. Following baseline, participants will attend a second visit and anthropometric and demographic information will be collected and we will measure blood pressure, the body composition by bioelectrical impedance analysis (BIA), and handgrip strength using a dynamometer.

Throughout the study, participants must complete a daily questionnaire to evaluate the transit time (eg. Bristol Stool Scale), stool frequency, and compliance. Every week, questionnaires to evaluate appetite (eg. SNAQ) and GI wellness (eg. GSRS - Gastrointestinal Symptom Response Scale) will be administered. During each study visit, participants will complete a questionnaire to evaluate the quality of life. In addition, the dietary data (24-hour diet recalls) will be collected by phone during the baseline week and during the last week of each period. During baseline, treatment and each washout, fasting blood will be collected and analyzed for a comprehensive metabolic panel with eGFR, in addition to microbial metabolites (e.g., indoxyl sulfate and p-cresyl sulfate), and inflammatory markers (e.g. CRP, TNFα, IL-6).
To the ESWT group, with the ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shock/session values was applied with a 15 mm head in a single session. Shock waves were applied directly to the most sensitive point detected in the medial of the calcaneus.